INDP
Indaptus Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 23 ▼ 1 insider sell $0.00
- May 15 ▼ Indaptus Therapeutics reported Q1 2026 results with a net loss of $2…
- Jul 20 ▼ Indaptus Therapeutics' S-3 registration statement (File No. 333-2970…
- Aug 14 ▼ Short interest jumps 32.9% to 123.7K
- Aug 17 ▼ Indaptus Therapeutics filed an S-3 registration statement to registe…
- Aug 26 ▼ The SEC declared effective Indaptus Therapeutics' S-3 registration (…
- Aug 31 ▼ Short interest jumps 71.6% to 212.4K
- Sep 4 ▼ Indaptus Therapeutics filed Amendment No. 1 to its August 31, 2026 p…
- Sep 9 ▼ Indaptus Therapeutics entered into a stock purchase agreement for a…
- Sep 15 ▼ Short interest jumps 331.5% to 916.4K
- Oct 20 ▼ Indaptus Therapeutics completed its previously announced private pla…
- Oct 30 ▼ Short interest jumps 33.0% to 1.14M
Signal stack
Where each data set points today.
- InsidersMIXED
No open-market sales.
- InstitutionsBULLISH
Q3 2026: 6 added (0 new), 1 trimmed or exited.
- Short sellersBUILDING
Short interest +33.0% to 1.14M shares. 4.0 days to cover, ≈0.7% of shares.
- TrendUPTREND
15% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $449.9K |
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | $312.7K |
| JANE STREET GROUP, LLC | ADD | $198.9K |
| UBS Group AG | DOUBLED | $191.7K |
| VANGUARD FIDUCIARY TRUST CO | DOUBLED | $150.2K |
| MORGAN STANLEY | NEAR_EXIT | $2.9K |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $169.4K |
| MORGAN STANLEY | DOUBLED | $26.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Nov 2024Price is below the lowest target. Median implies +190%.Targets as of Apr 28, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2024 | Maxim Group MAINTAIN | Buy |
| Oct 16, 2024 | HC Wainwright & Co. REITERATE | Buy |
| Jun 17, 2024 | HC Wainwright & Co. REITERATE | Buy |
| Apr 15, 2024 | HC Wainwright & Co. REITERATE | Buy |
| Sep 20, 2023 | HC Wainwright & Co. REITERATE | Buy |
| Aug 15, 2023 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Lazar David E. Director Mar 23, 2026 | SELL | 196,800 sh |
Lazar David E. Director Mar 23, 2026 | SELL | 700,000 sh |
Jabbour Jerome D Director Feb 26, 2026 | AWARD | 25,000 sh |
Meckler Jeffrey A Co-Chief Executive Officer Feb 11, 2026 | AWARD | 12,136 sh |
Meckler Jeffrey A Co-Chief Executive Officer Feb 11, 2026 | TO ISSUER | 3,033 sh |
Meckler Jeffrey A Co-Chief Executive Officer Feb 11, 2026 | TO ISSUER | 12,136 sh |
Meckler Jeffrey A Co-Chief Executive Officer Feb 11, 2026 | AWARD | 1,519 sh |
Meckler Jeffrey A Co-Chief Executive Officer Feb 11, 2026 | AWARD | 3,033 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 0 bullish · 11 bearish · 9 neutral- NEUTRAL PRESS-RELEASENov 13, 2026
Indaptus Therapeutics reported Q3 2026 net loss of $1.0M ($0.01 per share), narrowed from $3.0M…
The company is effectively exiting its core immunotherapy program (Decoy20) and pivoting to an early-stage neurotechnology device, a completely new direction with no clinical data. Monitor for…
- NEUTRAL SC 13D/AOct 22, 2026
Sino Lion Ventures Ltd and Chenhao Xu filed Amendment No. 3 to their Schedule 13D, reporting a…
The activist group's stake remains static at 38.9M shares, but their influence is diluted by the new issuance. Watch for any subsequent 13D amendments that signal a change in strategy, such as new…
- NEUTRAL SC 13D/AOct 22, 2026
Junyi Dai, CEO and Chairman of Indaptus Therapeutics, filed Amendment No. 3 to Schedule 13D…
This is a routine ownership update with no activist escalation. Monitor the company's post-private placement cash position and any strategic transaction announcements, as the 10-K noted plans for a…
- NEUTRAL SC 13D/AOct 22, 2026
Yun Yao filed Amendment No. 3 to her Schedule 13D, reporting a decrease in her beneficial…
This is a routine passive dilution filing with no activist escalation. Yao's stake remains large but static. Monitor for any future 13D amendments that signal a change in strategy or demands…
All INDP filing & press-release reports (20)
- PRESS-RELEASE reportNov 13, 2026
- SC 13D/A reportOct 22, 2026
- SC 13D/A reportOct 22, 2026
- SC 13D/A reportOct 22, 2026
- SC 13D/A reportOct 21, 2026
- 8-K reportOct 20, 2026
- 8-K reportSep 30, 2026
- 8-K reportSep 9, 2026
- 424B5 reportSep 4, 2026
- 8-K reportSep 1, 2026
- EFFECT reportAug 26, 2026
- S-3 reportAug 17, 2026
- 8-K reportAug 13, 2026
- EFFECT reportJul 20, 2026
- S-3 reportJun 26, 2026
- 8-K reportJun 24, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- 8-K reportApr 22, 2026
- 8-K reportApr 3, 2026